文献速递肝病

一项前瞻性多中心三队列研究评估肝硬化患者对比剂诱导的急性肾损伤(CI-AKI)

A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
PubMed 文献 · J Hepatol · 2023-10-20

该前瞻性多中心三队列研究纳入444例住院患者,其中肝硬化接受对比增强CT者148例(队列1)、肝硬化未暴露碘对比剂者133例(队列2)、无肝硬化接受对比增强CT者163例(队列3)。结果显示三组急性肾损伤发生率分别为4.8%、1.5%、2.5%,差异无统计学意义;合并感染是对比剂诱导急性肾损伤的唯一独立预测因素(OR 22.18,95%CI 2.87-171.22,P=0.003)。

要点

  • 肝硬化患者接受对比增强CT后急性肾损伤发生率低,与无肝硬化人群及未暴露碘对比剂的肝硬化人群无显著差异。
  • 合并感染是对比剂诱导急性肾损伤的唯一独立预测因素(OR 22.18,95%CI 2.87-171.22,P=0.003)。
  • 尿中性粒细胞明胶酶相关脂质运载蛋白在暴露前后无显著变化,提示急性肾损伤不伴肾小管损伤。

核心结论

  • 肝硬化患者接受对比增强CT后急性肾损伤风险低,与普通人群及未暴露碘对比剂的肝硬化人群无显著差异。
  • 急性肾损伤多为轻度且快速缓解的肾功能异常,不与肾小管损伤相关。
  • 合并活动性感染的患者似乎是唯一急性肾损伤风险显著升高的人群。

研究设计与样本

  • 前瞻性多中心队列研究,纳入444例住院患者:肝硬化接受对比增强CT者148例(队列1)、肝硬化未暴露碘对比剂者133例(队列2)、无肝硬化接受对比增强CT者163例(队列3)。
  • 在对比增强CT/入组时(T0)、48-72小时(T1)、5天和7天评估肾功能参数。
  • 从队列1和队列2各连续选取50例患者检测尿中性粒细胞明胶酶相关脂质运载蛋白作为肾小管损伤的早期生物标志物。

主要发现

  • 急性肾损伤发生率在队列1、队列2、队列3分别为4.8%、1.5%、2.5%,差异无统计学意义(p = n.s.)。
  • 多数急性肾损伤病例为轻度且一过性。
  • 合并感染是对比剂诱导急性肾损伤的唯一独立预测因素(OR 22.18;95%CI 2.87-171.22;p = 0.003)。
  • 尿中性粒细胞明胶酶相关脂质运载蛋白在T0至T1期间无显著变化,队列1中位数ΔU-NGAL为+0.2 [-7.6 至 +5.5] ng/ml,队列2为+0.0 [-6.8 至 +9.5] ng/ml(p = 0.682)。

临床怎么用

  • 作者认为,目前对肝硬化患者谨慎进行对比影像检查的推荐似乎不再合理,但合并感染的患者除外,其对比剂诱导急性肾损伤风险显著更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nephrotoxicity of intravenous iodinated contrast media (ICM) in cirrhosis is still a debated issue, due to scarce, low-quality and conflicting evidence. This study aims to evaluate the incidence and predisposing factors of acute kidney injury (AKI) in patients with cirrhosis undergoing contrast-enhanced computed tomography (CECT). METHODS: We performed a prospective, multicenter, cohort study including 444 inpatients, 148 with cirrhosis (cohort 1) and 163 without cirrhosis (cohort 3) undergoing CECT and 133 with cirrhosis (cohort 2) unexposed to ICM. Kidney function parameters were assessed at T0, 48-72 h (T1), 5 and 7 days after CECT/enrollment. Urinary neutrophil gelatinase-associated lipocalin (U-NGAL) was measured in 50 consecutive patients from cohort 1 and 50 from cohort 2 as an early biomarker of tubular damage. RESULTS: AKI incidence was not significantly increased in patients with cirrhosis undergoing CECT (4.8%, 1.5%, 2.5% in cohorts 1, 2, 3 respectively, p = n.s.). Most AKI cases were mild and transient. The presence of concomitant infections was the only independent predictive factor of contrast-induced AKI (odds ratio 22.18; 95% CI 2.87-171.22; p = 0.003). No significant modifications of U-NGAL between T0 and T1 were detected, neither in cohort 1 nor in cohort 2 (median ΔU-NGAL: +0.2 [-7.6 to +5.5] ng/ml, +0.0 [-6.8 to +9.5] ng/ml, respectively [p = 0.682]). CONCLUSIONS: AKI risk after CECT in cirrhosis is low and not significantly different from that of the general population or of the cirrhotic population unexposed to ICM. It mostly consists of mild and rapidly resolving episodes of renal dysfunction and it is not associated with tubular kidney injury. Patients with ongoing infections appear to be the only ones at higher risk of AKI. IMPACT AND IMPLICATIONS: Nephrotoxicity due to intravenous iodinated contrast media (ICM) in patients with cirrhosis is still a debated issue, as the available evidence is limited and based on very heterogeneous studies, often conducted on small and retrospective cohorts. In this prospective three-cohort study we found that intravenous administration of ICM was associated with a low risk of AKI, similar to that of the general population and to that of patients with cirrhosis unexposed to ICM. Patients with ongoing infections were the only ones to have a significantly increased risk of contrast-induced AKI. Therefore, the actual recommendations of performing contrast imaging studies cautiously in cirrhosis do not seem to be reasonable anymore, with the exception of infected patients, who have a significantly higher risk of contrast-induced AKI.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Campion D, Ponzo P, Risso A, et al. A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis. J Hepatol. 2023. PMID: 37865273. doi:10.1016/j.jhep.2023.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。